CytomX Therapeutics (NASDAQ:CTMX) Shares Down 4.2% on Disappointing Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s stock price traded down 4.2% during mid-day trading on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $6.42 and last traded at $6.4660. 3,381,211 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 5,457,485 shares. The stock had previously closed at $6.75.

The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

Wall Street Analyst Weigh In

CTMX has been the topic of a number of research reports. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $7.00 to $12.00 in a report on Monday. Wedbush raised their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday. Barclays lifted their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Cantor Fitzgerald increased their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Finally, Jefferies Financial Group raised their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.56.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC acquired a new position in shares of CytomX Therapeutics in the 2nd quarter worth approximately $19,208,000. Commodore Capital LP acquired a new stake in shares of CytomX Therapeutics during the second quarter worth $17,462,000. Perceptive Advisors LLC bought a new position in CytomX Therapeutics during the second quarter worth $15,876,000. Franklin Resources Inc. bought a new position in CytomX Therapeutics during the second quarter worth $13,096,000. Finally, Vivo Capital LLC acquired a new position in CytomX Therapeutics in the second quarter valued at $13,096,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

The firm has a market cap of $748.84 million, a price-to-earnings ratio of -110.00 and a beta of 2.44. The firm’s fifty day moving average is $5.27 and its 200-day moving average is $4.10.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.